Clinical trial
A Multi-center, Randomized, Blinded Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b Injection Combined With Tenofovir Disoproxil Fumarate Tablets in Patients With Chronic Hepatitis B
NCT04846491 is registered in ClinicalTrials.gov with Xiamen Amoytop Biotech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Blinded Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b Injection Combined With Tenofovir Disoproxil Fumarate Tablets in Patients With Chronic Hepatitis B
- Lead sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 4, 2019
- Completion date
- December 7, 2023
- Enrollment
- 475 (actual)
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.
chronic hepatitis b